基线HIV-1 RNA与病毒学抑制时间对一线ART后病毒学反弹的影响
OBJECTIVES: We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.…
要点
- 病毒学抑制时间>6个月与所有方案病毒学反弹强相关。
- EFV或INSTI方案较bPI方案病毒学反弹风险更低。
核心结论
- 启动一线cART的HIV-1感染者中,EFV或INSTI方案较bPI方案病毒学反弹风险更低。
研究设计与样本
- 一线cART为两种NRTI联合EFV、bPI或INSTI。
- 采用多因素调整的Cox比例风险模型和倾向评分匹配分析。
主要发现
- 病毒学抑制时间>6个月者较<6个月者病毒学反弹风险更高。
- EFV或INSTI方案较bPI方案病毒学反弹风险更低。
- 病毒学抑制时间>6个月与所有方案病毒学反弹强相关。
临床怎么用
- 一线cART可优先考虑EFV或INSTI方案以降低病毒学反弹风险。
- 对基线HIV-1 RNA高或病毒学抑制时间>6个月者应加强病毒学监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen. PATIENTS AND METHODS: Subjects were 10 836 adults who initiated first-line cART (two nucleoside or nucleotide reverse transcriptase inhibitors + efavirenz, a ritonavir-boosted protease inhibitor or an integrase inhibitor) from 1 January 2007 to 31 December 2014. Cox proportional hazards models with multiple adjustment and propensity score matching were used to investigate the effect of baseline HIV-1 RNA and time to virological suppression on the occurrence of virological rebound. RESULTS: During 411 436 patient-months of follow-up, risk of virological rebound was higher in patients with baseline HIV-1 RNA ≥100 000 copies/mL versus <100 000 copies/mL, in those achieving virological suppression in > 6 months versus <6 months, and lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. Baseline HIV-1 RNA >100 000 copies/mL was associated with virological rebound for ritonavir-boosted protease inhibitors but not for efavirenz or integrase inhibitors. Time to virological suppression >6 months was strongly associated with virological rebound for all regimens. CONCLUSIONS: In HIV-1-infected patients starting cART, risk of virological rebound was lower with efavirenz or integrase inhibitors than with ritonavir-boosted protease inhibitors. These data, from a very large observational cohort, in addition to the more rapid initial virological suppression obtained with integrase inhibitors, reinforce the positioning of this class as the preferred one for first-line therapy.
引用
- Raffi F, Hanf M, Ferry T, et al. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. J Antimicrob Chemother. 2017. PMID: 28961719. doi:10.1093/jac/dkx300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。